Aurobindo Pharma Limited
ICICI Prudential Mutual Fund has dropped off the latest shareholder list for Aurobindo Pharma Limited. Because filings only name investors holding over 1 percent, this shift represents either a complete exit or a reduction below that disclosure threshold.
A major manufacturer of active pharmaceutical ingredients and generic pharmaceuticals, Aurobindo Pharma produces a diverse range of pharmaceutical products serving domestic and international markets. The company operates across multiple therapeutic segments and maintains manufacturing facilities that comply with global quality standards. Its vertically integrated operations, coupled with significant research and development capabilities, distinguish it as a key player in India's pharmaceutical sector.
India's second-largest AMC by AUM with over Rs 9 lakh crore managed across 80+ schemes. Joint venture between ICICI Bank and Prudential plc. CIO S. Naren is one of India's most recognised value investors, known for contrarian macro calls and rotating across market caps well ahead of consensus. ICICI Pru's quarterly portfolio disclosures are among the most closely watched in the industry.